Thesis
Lumvoa approved and launched in TED; elegrobart BLA submission determines whether Viridian builds a two-drug franchise or peaks with one
Viridian launched Lumvoa, an FDA-approved IGF-1R inhibitor for thyroid eye disease, just weeks after completing its IPO, giving it a commercial asset and $982M in cash projected to sustain through profitability. Elegrobart, a subcutaneous anti-IGF-1R antibody, met primary endpoints in both active and chronic TED Phase 3 trials; approvability on that single-arm-style BLA filing determines whether Viridian captures a second, more convenient formulation franchise. The core risk is competition from Amgen's Tepezza, which already has entrenched prescriber relationships and a head start that a subcutaneous convenience argument alone may not overcome.
Focus
Elegrobart BLA submission for thyroid eye disease
Q1 2027
Bull
A clean BLA submission in Q1 2027 incorporating the strong REVEAL-1 and REVEAL-2 data — proptosis responder rates of 50-63% versus 15-18% placebo across both active and chronic TED, combined with a favorable safety profile and low hearing impairment rates — would position elegrobart for FDA review and potential approval as a subcutaneous alternative to intravenous Lumvoa. A successful filing would validate the two-drug franchise thesis, expand the addressable market by reaching patients who prefer or require subcutaneous administration, and materially increase Viridian's peak revenue potential and competitive durability in TED.
Bear
The most likely failure modes are a Complete Response Letter or a request for additional data driven by questions around the hearing impairment signal (8.8% placebo-adjusted in the Q8W arm), manufacturing or chemistry, manufacturing, and controls deficiencies in the subcutaneous formulation, or FDA requiring a dedicated subcutaneous bridging or immunogenicity dataset not yet included in the package. A delayed or refused-to-file BLA would collapse the two-drug franchise narrative and raise concerns about whether elegrobart can ever achieve approval, leaving Lumvoa as the sole revenue driver and potentially pressuring peak sales estimates.
Unlock the full thesis for VRDN.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.